Skip to content
value.today

Strata Skin Sciences, Inc.

SSKN
$22 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$31 M
For year ending December-2025
Net income
$-6 M
-20.4% margin
SEC filing
Employees
—

Strata Skin Sciences, Inc. in brief

Strata Skin Sciences, Inc. is a listed company in the Medical Devices industry, based in Horsham, Pennsylvania, USA. It was founded in 1989. Its last known market value was $22 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $31 M and a net loss of $6 M. Its largest business segments by sales in 2025 were Dermatology Recurring Procedures (70%) and Dermatology Procedures Equipment (30%). By market, the largest shares of its 2025 sales came from USA (67%), China (11%) and Middle East (6%). Its shares trade under the symbol SSKN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Strata Skin Sciences, Inc.

Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.

The company's flagship product, XTRAC, is a medical device that allows for a trained dermatologist to treat skin conditions like Vitiligo and Psoriasis with monochromatic UV Light. Following completion of a successful conformity assessment procedure, Strata Skin Sciences has also been granted CE Mark approval for sale of MelaFind in the European Union.

In July 2015, the company acquired PhotoMedex Inc. and is planning to relocate its headquarters from Irvington, New York to Horsham, Pennsylvania in Montgomery County.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Strata Skin Sciences, Inc. timeline

7 events, 1989–2022
  1. 1989
  2. 🏁
    Founded
  3. 2003
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2005
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 2010
  8. ✎
    Renamed Mela Sciences, Inc.
    Formerly Electro Optical Sciences Inc.
  9. 2016
  10. ✎
    Renamed STRATA Skin Sciences, Inc.
    Formerly Mela Sciences, Inc..
  11. 📈
    · approximate
    Listed on Nasdaq as SSKN
  12. 2022
  13. 💰
    Record revenue of $36 million
    FY2022, the highest of the 8 years on record.

Events of Strata Skin Sciences, Inc. from Wikidata, SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$18 M$37 M$55 M$73 M20202021202220232024

World rank over time

▼ down 7,960 places since 2020
2020-01-01: #20531#20,53120202021-01-01: #20647#20,64720212022-01-07: #26998#26,99820222022-12-25: #27728#27,72820222023-07-30: #27302#27,30220232024-01-05: #28491#28,4912024

Rank in USA: #3,943 (Jan 2020) · #4,056 (Jan 2021) · #4,940 (Jan 2022) · #5,093 (Dec 2022) · #4,970 (Jul 2023) · #4,334 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-20.4%
Operating margin
-15.3%
Return on equity
-215.1%
Liabilities / assets
90.5%
Net debt
$7M
Revenue growth
-8.5%
R&D / revenue
1.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $30M, net income $-4M$30MFY18Fiscal year ending Dec 2019: revenue $32M, net income $-4M$32MFY19Fiscal year ending Dec 2020: revenue $23M, net income $-4M$23MFY20Fiscal year ending Dec 2021: revenue $30M, net income $-3M$30MFY21Fiscal year ending Dec 2022: revenue $36M, net income $-6M$36MFY22Fiscal year ending Dec 2023: revenue $33M, net income $-11M$33MFY23Fiscal year ending Dec 2024: revenue $34M, net income $-10M$34MFY24Fiscal year ending Dec 2025: revenue $31M, net income $-6M$31MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$31M-8.5%$-5M$-6M-20.4%
Dec 2024$34M+0.6%$-9M$-10M-30.1%
Dec 2023$33M-7.7%$-9M$-11M-32.5%
Dec 2022$36M+20.6%$-5M$-6M-15.3%
Dec 2021$30M+29.8%$-4M$-3M-9.0%
Dec 2020$23M-26.9%$-4M$-4M-19.1%
Dec 2019$32M+5.8%$-3M$-4M-12.0%
Dec 2018$30M—$-3M$-4M-13.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-3M$1M$-4M$-1.35—
Dec 2024$0M$2M$-1M$-2.65—
Dec 2023$-1M$5M$-6M$-3.10—
Dec 2022$-1M$4M$-5M$-0.16—
Dec 2021$2M$4M$-2M——
Dec 2020$2M$2M$-0M$-0.13—
Dec 2019$2M$0M$2M$-0.11—
Dec 2018$3M——$-0.15—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$31M
Net income, trailing 12 months
$-6M
RevenueNet income
Three months to Mar 2024: revenue $7M, net income $-3M$7MMar ’24Three months to Jun 2024: revenue $8M, net income $-0M$8MJun ’24Three months to Sep 2024: revenue $9M, net income $-2M$9MSep ’24Three months to Dec 2024 (from the annual report): revenue $10M, net income $-5M$10MDec ’24Three months to Mar 2025: revenue $7M, net income $-2M$7MMar ’25Three months to Jun 2025: revenue $8M, net income $-3M$8MJun ’25Three months to Sep 2025: revenue $7M, net income $-2M$7MSep ’25Three months to Dec 2025 (from the annual report): revenue $9M, net income $0M$9MDec ’25

Latest quarter to Dec 2025: revenue $9M (-2.8% on a year earlier), net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2025.

SEC filings

Official filings of Strata Skin Sciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$31 M
Operating income
$-5 M
Net income
$-6 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$31 M
Total liabilities
$28 M
Total equity
$3 M

As of December-2025

Insider trading at Strata Skin Sciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
39
since
$784 K-$19 K$0Nov 2023: bought $0 (0 trades), sold $320 (1 trades)Nov 23Dec 2023: bought $9 K (4 trades), sold $0 (0 trades)DecJul 2024: bought $784 K (3 trades), sold $0 (0 trades)JulNov 2025: bought $7 K (2 trades), sold $19 K (3 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Strata Skin Sciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Samuel RubinsteinDirectorBuy+2,168$1.400$3 K5,934Form 4
filed Samuel RubinsteinDirectorBuy+2,832$1.410$4 K8,766Form 4
filed Samuel RubinsteinDirectorSell-5,500$1.320$7 K12,360Form 4
filed Samuel RubinsteinDirectorSell-7,200$1.340$10 K5,160Form 4
filed Samuel RubinsteinDirectorSell-1,394$1.360$2 K3,766Form 4
filed Uri GeigerDirector, 10% ownerBuyindirect+230,573$3.140—1.44 MForm 4
filed Accelmed Growth Partners (AGP) Ltd10% ownerBuy+230,573$3.140$724 K1.44 MForm 4
filed Dolev RafaeliChief Executive Officer, DirectorBuy+19,100$3.140$60 K143,156Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Strata Skin Sciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
58,986
1.0% of shares · 2.23 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-5 reverse split ; 1-for-10 reverse split in the period to ; 1-for-10 reverse split

Trading halts

  • 2025-08-27 19:22 UTC, code LUDP, resumed 19:27 UTC

Fails to deliver

  • : 3 shares
  • : 21 shares
  • : 57 shares
  • : 129 shares
  • : 5 shares at $0.13

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Strata Skin Sciences, Inc. scorecard#

Passes 0 of the 15 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-8.5%Revenue down 8.5% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-5.3%-5.3% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-5.3%-5.3% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-1.35 vs -2.65Diluted EPS -1.35 in fiscal 2025 against -2.65 the year before (report's currency).
    • ✗Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$4 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-15.3%-15.3% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-158.9%-158.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-15.3%-15.3% in fiscal 2025 against -12.9% in 2022.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.6×Current ratio 0.58 at the end of fiscal 2025.
    • ✗Debt below equity5.3×Debt to equity 5.27 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year22.2%Diluted shares up 22.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Strata Skin Sciences, Inc.'s statements, beside the median of Medical Devices.

Strata Skin Sciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-15.3%-8.2%
Net margin-20.4%-10.4%
Return on equity-158.9%-16.8%
Revenue growth, 3 years a year-5.3%10.8%
Revenue growth-8.5%10.4%
Debt to equity5.27×0.64×

5of 9on the Piotroski tests of financial strength

  • Revenue fell 8.5% against the year before.
  • Net loss of $6 million, the 17th loss-making year in a row.
  • Free cash flow was negative: -$4 million.
  • The share count rose 22.2% in the year.

Strata Skin Sciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Strata Skin Sciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue313433363023323032r31r
Cost of revenue1314r1514109.0111313r13
Gross profit1819r18222014201719r18r
Research and development0.40.91.31.01.41.31.01.11.71.9
Selling and marketing1312r1315139.012111112r
General and administrative1011r11109.77.9108.87.6r7.6
Operating expenses————2418232021r22r
Total costs and expenses2328r272624—————
Operating income−4.7−9.3−8.6−4.6−4.4−4.1−3.0−3.4−1.8r−3.6
Interest and finance income0.40.20.20.10.00.2————
Interest expense and finance costs2.02.11.60.90.30.20.51.13.2r4.9
Net interest income—————−0.1−0.5———
Other non-operating income (expense)−1.5−1.0−2.3−0.81.7−0.1−0.9−0.9−20r0.5
Income before tax−6.2−10−11−5.5−2.7−4.1−3.9−4.3−21r−3.1
Income tax0.0−0.2−0.10.10.00.3−0.1−0.30.10.3
Net income attributable to shareholders−6.3−10−11−5.5−2.7−4.4−3.8−4.0−22r−3.3
Earnings per share, basic-1.35-2.65-3.10r-0.16—-0.13-0.11-0.15-3.26r-1.57r
Earnings per share, diluted-1.35-2.65-3.10r-0.16—-0.13-0.11-0.15-3.26r-3.77r
Shares, weighted average (basic)4.73.83.5r35—3432202.72.1r
Shares, weighted average (diluted)4.73.83.5r35—3432202.72.3r
Balance sheet
Cash and cash equivalents7.97.36.85.413118.1164.13.9
Receivables4.15.34.44.53.42.94.43.43.13.4
Inventory2.82.22.73.1r3.53.43.02.83.02.8
Other current assets0.80.50.30.70.50.30.50.50.50.6
Current assets16171615r202524231111
Property, plant and equipment9.0101210.0r6.95.55.45.37.710
Right-of-use (leased) assets0.91.30.61.00.61.01.30——
Goodwill1.41.4r6.58.88.88.88.88.88.88.8
Other intangible assets3.45.37.317106.38.09.812r13r
Total assets3135r42524747474839r43
Accounts payable2.82.43.33.42.82.81.91.82.31.9
Debt due within a year150——01.500.32.41.7
Current liabilities2713r12131319178.610r9.0r
Long-term debt015157.57.31.107.17.99.8
Lease liabilities (non-current)0.70.90.20.60.40.71.10——
Total liabilities2830r29302121191619r28r
Retained earnings−254−248−238−227−222−219−215−211−204r−182r
Shareholders' equity2.95.013222526293120r15r
Total liabilities and equity3135r42524747474839r43
Shares outstanding5.94.23.5r35343433304.32.2r
Cash-flow statement
Depreciation and amortization4.15.05.65.3r2.12.0r2.73.64.34.6
Share-based compensation0.60.41.31.51.61.61.20.90.20.1
Cash from operating activities−2.80.2−0.5−0.9r1.52.12.22.94.10.3
Capital expenditure−1.5−1.6−5.0−3.7r−3.7−2.2r−0.1———
Acquisitions, net of cash acquired——0−0.6−3.50——0−0.1
Cash from investing activities−1.5−1.6−5.0−4.4r−7.1−2.2−2.8−1.8−2.2−0.9
Debt issued—07.008.02.5——01.5
Debt repaid———0−0.50−7.6−3.0−1.40
Shares issued3.61.90———0170—
Cash from financing activities3.61.96.9−0.50.12.5−0.311−1.81.2
Exchange-rate effect on cash———————0−0.00.0
Change in cash−0.70.51.3−5.8−5.52.5−0.9120.10.6
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Strata Skin Sciences, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Dermatology Recurring Procedures$21 M70%
  • Dermatology Procedures Equipment$9 M30%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Strata Skin Sciences, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Strata Skin Sciences, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters2 offices$21 M67%
🇨🇳 China$3 M11%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Strata Skin Sciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2024
$601 K
Other top executives, average
$297 K
the CEO earned 2× this
$100 invested is now
$20
Strata Skin Sciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2024Chief executive$601 K$133 K$297 K$20
2023Chief executive$1.0 M$840 K$693 K$37
2022Mr. Robert Moccia$983 K−$194 K$642 K$53

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024

Events at Strata Skin Sciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling
  • Delisting noticeFiling

Delisting notice 4 · Auditor changed 1 · Directors and officers 1 · Material agreement 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

Strata Skin Sciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Shareholder vote8-K
Results announced8-K
Delisting notice8-K
Material agreement8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Directors and officersResults announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Feb 11, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Strata Skin Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$17 MPrivate placement after listing$10 to $50 million—equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Product recalls by Strata Skin Sciences, Inc.#

1 recalls since 2015, 1,000 units in the notices that give a number. Medical devices (FDA): 1.

Strata Skin Sciences, Inc.: product recalls
DateWhat and whyUnitsNotice
XTRAC Excimer Laser, Model No. AL8000, AL10000 The intended use is targeted UVB phototherapy for treatment of the skin conditions including psoriasis, vitiligo, atopic dermatitis, and leukoderma.When the Liquid Guide ( LLG) is not used according to the operator manual, the switch control wires may become loose and shorted. Shorted wires may lead to unintentional laser firing.Medical devicesClass II1,000Z-1455-2017

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

How Strata Skin Sciences, Inc. compares in Medical Devices

  • Revenue$31 M · higher than 23% of 155
  • Net margin-20.4% · higher than 36% of 144
  • Revenue growth-8.5% · higher than 9% of 104

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Strata Skin Sciences, Inc.🇺🇸$22 M—-20.4%-8.5%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Strata Skin Sciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Strata Skin Sciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Strata Skin Sciences, Inc.? Suggest a correction